This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the "Mitigating Delirium with Fluvoxamine Treatment for Non-Cardiac Surgery (MD FLUNCS): Feasibility Trials & Mechanistic Insights" research project. The $430,850 award will fund a feasibility study to evaluate the use of the antidepressant fluvoxamine as a potential intervention to mitigate the risk of postoperative delirium, which is linked to systemic inflammation, neuroinflammation, and altered synaptic plasticity. The research, led by Washington University in St. Louis, will include a sub-award to the University of Sydney to serve as an enrolling site for the clinical trial. The goal is to establish the biological plausibility and infrastructure for a larger-scale clinical trial to assess fluvoxamine's efficacy in reducing delirium risk and potential progression to Alzheimer's disease and related dementias. The project period runs from Sep 2024 to May 2026.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $0 | 4/18/25 | ||
| Not listed | $215.4k | 9/9/24 | ||
| Not listed | $215.4k | 9/9/24 |
Grant Number | Description | Subgrantee | Prime Award | Dollars Obligated (Click to sort descending) | Updated At (Click to sort ascending) |
|---|---|---|---|---|---|
WU250462S | University Of Sydney | Project Grant R21AG086855 | $72.1k | 3/13/25 |